Another F-1A from Todos: IPO now down to $4,000,00
Post# of 30066
(Total Views: 660)
Posted On: 09/06/2019 11:03:04 AM
.jpg)
Another F-1A from Todos: IPO now down to $4,000,000
https://www.sec.gov/Archives/edgar/data/16452...edical.htm
On the positive side: Shares Outstanding DROPPED to 235,854,121
https://www.otcmarkets.com/stock/AMBS/security
Strongly suggests execution of the following:
On December 19th, 2018, the Company entered into a term sheet with Mr. Heng Fai Chan to redeem certain securities held by Mr. Chan, in exchange for the issuance of new securities. Under the terms of the agreement the following securities held by Mr. Chan will be returned to the Company:
o 25,530,667 shares of common stock held in the name of Xpress Group International Ltd, representing approximately
o 250,000 shares of Series F Preferred Stock, and the 25,000,000,000 common share voting rights related thereto, held by Amarantus Bioscience PTE Ltd. (an entity wholly-owned by Mr. Chan)
In exchange the Company will issue to Mr. Chan:
o 99 shares of Series C stock, which will convert into 9.9% of Company common stock, inclusive of any shares outstanding held by Mr. Chan, or affiliates of Mr. Chan. The conversion shall upon the earlier of at the discretion of the holder, or immediately prior to a listing of Company common stock on a national exchange. The conversion shall be a one-time conversion, which means that the holder is entitled to convert the Series C only in a single transaction. This class of Series C stock is in process of being created
o 10% of subsidiary Elto Pharma
o 10% of subsidiary Cutanogen Corporation
o 10% of subsidiary Breakthrough Diagnostics
https://backend.otcmarkets.com/otcapi/company...40/content
https://www.sec.gov/Archives/edgar/data/16452...edical.htm
On the positive side: Shares Outstanding DROPPED to 235,854,121
https://www.otcmarkets.com/stock/AMBS/security
Strongly suggests execution of the following:
On December 19th, 2018, the Company entered into a term sheet with Mr. Heng Fai Chan to redeem certain securities held by Mr. Chan, in exchange for the issuance of new securities. Under the terms of the agreement the following securities held by Mr. Chan will be returned to the Company:
o 25,530,667 shares of common stock held in the name of Xpress Group International Ltd, representing approximately
o 250,000 shares of Series F Preferred Stock, and the 25,000,000,000 common share voting rights related thereto, held by Amarantus Bioscience PTE Ltd. (an entity wholly-owned by Mr. Chan)
In exchange the Company will issue to Mr. Chan:
o 99 shares of Series C stock, which will convert into 9.9% of Company common stock, inclusive of any shares outstanding held by Mr. Chan, or affiliates of Mr. Chan. The conversion shall upon the earlier of at the discretion of the holder, or immediately prior to a listing of Company common stock on a national exchange. The conversion shall be a one-time conversion, which means that the holder is entitled to convert the Series C only in a single transaction. This class of Series C stock is in process of being created
o 10% of subsidiary Elto Pharma
o 10% of subsidiary Cutanogen Corporation
o 10% of subsidiary Breakthrough Diagnostics
https://backend.otcmarkets.com/otcapi/company...40/content
(2)
(1)